ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: As described in our previous work (Wei et al., 2020), OGP46 has been shown to induce cell differentiation and inhibit the cell proliferation of chronic myeloid leukemia (CML) cell lines expressing native BCR-ABL and mutant BCR-ABL, including T315I through the BCR-ABL/JAKSTAT pathway by depleting the BCR-ABL oncogene.